Copox
Phase 2
Copox is one of 7 therapeutic programs targeting Gastric Cancer (GC). It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
6 competitors in Gastric Cancer (GC)
#DrugCompanyPhaseTrials
1Injectafer
AAmerican Regent, Inc.
Approved
Venofer
AAmerican Regent, Inc.
Approved
SHR-1701
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 2
Copox
CCancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
TAS102
UUniversity of Wisconsin, Madison
Phase 2
NK510
BBase Therapeutics (Shanghai) Co., Ltd.
Phase 1
Retlirafusp Alfa
TTang-Du Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Gastric Cancer (GC)1 trial
Safety and Efficacy of Radiotherapy Combined With Chemotherapy and SHR-1701, a PD-L1(Programmed Death-Ligand 1)/TGF-β(Transforming Growth Factor-beta) Bispecific Antibody, in the Treatment of Unresectable Locally Advanced or Metastatic Gastric Cancer
Recruiting·CCancer Institute and Hospital, Chinese Academy of Medical Sciences·Phase 2·NCT07689851·60 enrolled
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Copox. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]